| Autor: |
Ducceschi M; Gynecological Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy., Polignano M; Gynecological Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy., Bini M; Gynecological Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy., Lopez S; Gynecological Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy., Conca E; Department of Innovation Diagnostics, Laboratory of Molecular Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy., Tamborini E; Department of Innovation Diagnostics, Laboratory of Molecular Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy., Perrone F; Department of Innovation Diagnostics, Laboratory of Molecular Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy., Carlo Stella G; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy., Petrella MC; Oncologia Medica Ginecologica, Azienda Ospedaliera Universitaria Careggi, 50134 Firenze, Italy., Carciotto R; Oncologia Medica, Ospedale Maria Paternò Arezzo, 97100 Ragusa, Italy., Artioli G; Oncologia Medica, Ospedale Cà Foncello, 31100 Treviso, Italy., Maffeis V; Anatomia Patologica, Ospedale Cà Foncello, 31100 Treviso, Italy., Sartor L; Oncologia Medica, Ospedale Camposampiero e Cittadella (Padova) ULSS 6, 35012 Euganea, Italy., Raspagliesi F; Gynecological Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy., Mantiero M; Gynecological Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy. |
| Abstrakt: |
Patients with solid tumors and mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) are eligible for immunotherapy. Recently, different reports described patients with poor performance status (PS), unrelated to comorbidities, which showed a rapid improvement of their clinical conditions under immunotherapy, which evoked a Lazarus response. Very few data on the efficacy and safety of immunotherapy in patients with gynecological malignancies and poor PS are available. Based on the GARNET trial, Dostarlimab, a monoclonal antibody anti-programmed death receptor-1 (PD-1), has been approved in advanced or recurrent mismatch repair deficient endometrial cancer (EC) which progressed after platinum-based therapy. For the first time, in gynecological oncology, an immune checkpoint inhibitor drastically changed the clinical practice. We collected a multicenter case series of six patients with advanced endometrial carcinoma and PS ECOG 3-4 treated with Dostarlimab, showing exceptionally quick responses and significant improvement of PS to configure a Lazarus response. |
